Tetraphase Pharmaceuticals to Present at the Annual UBS Global Healthcare Conference
Tetraphase Pharmaceuticals to Present at the Annual UBS Global Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (NAS: TTPH) , a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) gram-negative pathogens), today announced that Tetraphase Senior Vice President & Chief Financial Officer David Lubner will present at the annual UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 AM a.m. Eastern Time. The conference will take place at The Sheraton Hotel in New York City.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections.
Investors:
Tetraphase Pharmaceuticals
David Lubner, 617-715-3551
Senior Vice President & CFO
dlubner@tphase.com
or
Argot Partners
Susan Kim, 212-600-1902
susan@argotpartners.com
or
Media:
Sam Brown Inc.
Mike Beyer, 773-463-4211
beyer@sambrown.com
KEYWORDS: United States North America Massachusetts New York
INDUSTRY KEYWORDS:
The article Tetraphase Pharmaceuticals to Present at the Annual UBS Global Healthcare Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
